Figure 2: Network diagram of studies comparing clinical objective response (COR) of different neoadjuvant endocrine therapy (NET) therapies for HR-positive breast cancer. | Scientific Reports

Figure 2: Network diagram of studies comparing clinical objective response (COR) of different neoadjuvant endocrine therapy (NET) therapies for HR-positive breast cancer.

From: Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer

Figure 2

Each link represents at least 1 study and the widths of each link are proportional to the number of studies comparing the particular arms. The size of each node is proportional to the total sample size. CT = chemotherapy, Ana = anastrozole, Tam = tamoxifen, Gef = gefitinib, Let = letrozole, Exe (<20wks) = Exemestane (<20wks), Exe (≥20wks) = Exemestane ((≥20wks), Cel = Celecoxib, Eve = Everolimus.

Back to article page